PULSAR and STELLAR trials have shown favorable effects on functional class, NT-proBNP, and hemodynamics, and therefore sotatercept was approved by the Food And Drug Administration for treating patients with PAH [81,82,83]. Here, NPPB is linked to pulmonary arterial hypertension.